InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

Current share price for MYX : $3.120 0.05 (1.58%)+

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$253 2026 Full Year Results Investor Presentation 27 Aug 2026 8:44AM $3.170 $3.120 fallen by 1.58%
$253 2026 Corporate Governance Statement and Appendix 4G 27 Aug 2026 8:43AM $3.170 $3.120 fallen by 1.58%
$253 2026 Full Year Results Media Release 27 Aug 2026 8:42AM $3.170 $3.120 fallen by 1.58%
$253 2026 Appendix 4E and Annual Report 27 Aug 2026 8:40AM $3.170 $3.120 fallen by 1.58%
$253 Notification of date for release of FY26 results 21 Aug 2026 12:56PM $3.270 $3.120 fallen by 4.59%
$253 Upcoming presentation of Imvexxy clinical data 20 Aug 2026 8:59AM $3.230 $3.120 fallen by 3.41%
$253 Mayne Pharma launches Investor Hub 18 Aug 2026 9:16AM $3.300 $3.120 fallen by 5.45%
$253 Initial Director's Interest Notice 14 Aug 2026 5:13PM $3.200 $3.120 fallen by 2.50%
$253 Mayne Pharma Bioshares Summit Presentation 5 Aug 2026 5:20PM $3.130 $3.120 fallen by 0.32%
$253 Notification of cessation of securities - MYX 5 Aug 2026 5:14PM $3.130 $3.120 fallen by 0.32%
$253 Notification regarding unquoted securities - MYX 5 Aug 2026 5:14PM $3.130 $3.120 fallen by 0.32%
$253 Non-Executive Director appointment 5 Aug 2026 1:35PM $3.030 $3.120 risen by 2.97%
$253 Mayne Pharma to present at the 20th Bioshares Summit 3 Aug 2026 3:46PM $2.920 $3.120 risen by 6.85%
$253 Mayne Pharma reports unaudited Q4 and FY26 results 31 Jul 2026 9:29AM $2.600 $3.120 risen by 20%
$253 Mayne Pharma appoints new Chief Financial Officer 17 Jul 2026 8:53AM $2.920 $3.120 risen by 6.85%
$253 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $3.120 risen by 11.83%
$253 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $3.120 risen by 11.83%
$253 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $3.120 risen by 11.83%
$253 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $3.120 risen by 11.83%
$253 Initial Director's Interest Notice 1 Jul 2026 9:38AM $2.790 $3.120 risen by 11.83%
$253 Mayne Pharma appoints new Non-Executive Director 26 Jun 2026 9:15AM $2.390 $3.120 risen by 30.54%
$253 Change in substantial holding 26 Jun 2026 9:11AM $2.390 $3.120 risen by 30.54%
$253 Change in substantial holding 18 Jun 2026 2:57PM $2.320 $3.120 risen by 34.48%
$253 Final Director's Interest Notice 5 Jun 2026 3:51PM $2.315 $3.120 risen by 34.77%
$253 Mayne Pharma receives $14.4m for legal costs from Cosette 5 Jun 2026 10:44AM $2.210 $3.120 risen by 41.18%

1 - 25 of 895 results

Page 1 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.